The combination of radiotherapy with immune-modulating agents could enhance the effectiveness of radiation in treating oligometastatic breast cancer by shifting the balance away from the immunosuppressive effects using anti-LAG3 and anti-CSF1R agents and simultaneously enhancing the immunostimulatory effects via checkpoint inhibition with anti-PD-1/PD-L1 and increased T cell survival with 4-1BB agonists. The gene discussed is CSF1R; the disease is breast cancer.